ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

HEMO Hemogenyx Pharmaceuticals Plc

1.425
-0.026 (-1.79%)
14 Jun 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Hemogenyx Pharmaceuticals Plc LSE:HEMO London Ordinary Share GB00BYX3WZ24 ORD GBP0.01
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.026 -1.79% 1.425 1.402 1.448 1.42 1.41 1.42 3,614,132 16:35:13
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Finance Services 0 -6.69M -0.0059 -2.39 16.1M
Hemogenyx Pharmaceuticals Plc is listed in the Finance Services sector of the London Stock Exchange with ticker HEMO. The last closing price for Hemogenyx Pharmaceuticals was 1.45p. Over the last year, Hemogenyx Pharmaceuticals shares have traded in a share price range of 1.125p to 6.30p.

Hemogenyx Pharmaceuticals currently has 1,141,999,321 shares in issue. The market capitalisation of Hemogenyx Pharmaceuticals is £16.10 million. Hemogenyx Pharmaceuticals has a price to earnings ratio (PE ratio) of -2.39.

Hemogenyx Pharmaceuticals Share Discussion Threads

Showing 11201 to 11220 of 13425 messages
Chat Pages: Latest  453  452  451  450  449  448  447  446  445  444  443  442  Older
DateSubjectAuthorDiscuss
10/1/2022
11:21
Pikey....next stop 1.80p bid .... especially when MadVlad opens his gob........
badger60
10/1/2022
11:13
To stay up to date you can register with the link below for the H.C. Wainwright BIOCONNECT Virtual Conference Starts this Monday 10th January till the 13th January 2022

hxxps://my.ct.events/register.aspx?meid=22d2962c-a482-43a2-8aad-53f12bd1b3da&;rpid=41d6be82-5fdd-4e3a-b857-a774c4e1a118

As per last RNS:
Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, is pleased to announce its participation in the H.C. Wainwright Bioconnect Conference, in which the Company will be featured as a presenting company. The conference will be held on a virtual platform from January 10-13, 2022.


As part of the Company's presentation, Dr. Vladislav Sandler, CEO of Hemogenyx Pharmaceuticals, will provide an overview of the Company's business and product candidates to conference attendees.

If you are an institutional investor and would like to listen to the Company's presentation, please click on the following link to register for the conference: hxxps://hcwevents.com/bioconnect/.

The conference will feature corporate presentations and panels both live and on-demand. Dr. Sandler's presentation is accessible using a webcast link.


Dr Vladislav Sandler, CEO & Co-Founder of Hemogenyx Pharmaceuticals, commented: "Our presentation at the H.C. Wainwright Bioconnect Investment Conference provides the Company with a great opportunity to inform the investment community about our achievements and increase the Company's visibility globally. It also allows us to further establish Hemogenyx Pharmaceuticals as a leader in the development of medicines for the treatment of blood and autoimmune diseases."

About Hemogenyx Pharmaceuticals plc

Hemogenyx Pharmaceuticals is a publicly traded company (LSE: HEMO) headquartered in London, with its US operating subsidiaries, Hemogenyx Pharmaceuticals LLC and Immugenyx LLC, located in New York City at its state-of-the-art research facility.



The Company is a pre-clinical stage biopharmaceutical group developing new medicines and treatments to treat blood and autoimmune disease and to bring the curative power of bone marrow transplantation to a greater number of patients suffering from otherwise incurable life-threatening diseases. Hemogenyx Pharmaceuticals is developing several distinct and complementary product candidates, as well as a platform technology that it uses as an engine for novel product development.



For more than 50 years, bone marrow transplantation has been used to save the lives of patients suffering from blood diseases. The risks of toxicity and death that are associated with bone marrow transplantation, however, have meant that the procedure is restricted to use only as a last resort. The Company's technology has the potential to enable many more patients suffering from devastating blood diseases such as leukemia and lymphoma, as well as severe autoimmune diseases such as multiple sclerosis, aplastic anemia and systemic lupus erythematosus (Lupus), to benefit from bone marrow transplantation.


About H.C. Wainwright & Co.

H.C. Wainwright is a full‐service investment bank dedicated to providing corporate finance, strategic advisory and related services to public and private companies across multiple sectors and regions. H.C. Wainwright & Co. also provides research and sales and trading services to institutional investors. According to Sagient Research Systems, H.C. Wainwright's team is ranked as the #1 Placement Agent in terms of aggregate CMPO (confidentially marketed public offering), RD (registered direct offering) and PIPE (private investment in public equity) executed cumulatively since 1998.

checkricky
10/1/2022
11:00
Should be dropping to 1.9 bid soon.....has Vlad started his drivel yet?
badger60
10/1/2022
10:55
Hi Catsan......Pikey will sort you out....... literally. What do you want, and how long do you want to stay in hospital?.........;+)
badger60
10/1/2022
10:10
Good morning, I registered as I was curious to watch but having been told I Was successfully registered I am expecting some sort of email? I click login and I am told to follow instructions in an email but I have no email, has anyone else been able to successfully get access?
catsan
10/1/2022
09:58
Thanks Ash the link below is all good just checked

hxxps://my.ct.events/register.aspx?meid=22d2962c-a482-43a2-8aad-53f12bd1b3da&;rpid=41d6be82-5fdd-4e3a-b857-a774c4e1a118

checkricky
10/1/2022
09:52
Checkricky you don't need to put Xs in web links
ashleyjv
10/1/2022
09:43
Pikey....your link doesn't work.....hardly surprising, very much like Hemocasino
badger60
10/1/2022
08:30
hxxps://my.ct.events/register.aspx?meid=22d2962c-a482-43a2-8aad-53f12bd1b3da&;rpid=41d6be82-5fdd-4e3a-b857-a774c4e1a118
checkricky
10/1/2022
08:29
To stay up to date you can register with the link below for the H.C. Wainwright BIOCONNECT Virtual Conference Starts this Monday 10th January till the 13th January 2022

hxxps://my.ct.events/register.aspx?meid=22d2962c-a482-43a2-8aad-53f12bd1b3da&;rpid=41d6be82-5fdd-4e3a-b857-a774c4e1a118

As per last RNS:
Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, is pleased to announce its participation in the H.C. Wainwright Bioconnect Conference, in which the Company will be featured as a presenting company. The conference will be held on a virtual platform from January 10-13, 2022.


As part of the Company's presentation, Dr. Vladislav Sandler, CEO of Hemogenyx Pharmaceuticals, will provide an overview of the Company's business and product candidates to conference attendees.

If you are an institutional investor and would like to listen to the Company's presentation, please click on the following link to register for the conference: hxxps://hcwevents.com/bioconnect/.

The conference will feature corporate presentations and panels both live and on-demand. Dr. Sandler's presentation is accessible using a webcast link.


Dr Vladislav Sandler, CEO & Co-Founder of Hemogenyx Pharmaceuticals, commented: "Our presentation at the H.C. Wainwright Bioconnect Investment Conference provides the Company with a great opportunity to inform the investment community about our achievements and increase the Company's visibility globally. It also allows us to further establish Hemogenyx Pharmaceuticals as a leader in the development of medicines for the treatment of blood and autoimmune diseases."

About Hemogenyx Pharmaceuticals plc

Hemogenyx Pharmaceuticals is a publicly traded company (LSE: HEMO) headquartered in London, with its US operating subsidiaries, Hemogenyx Pharmaceuticals LLC and Immugenyx LLC, located in New York City at its state-of-the-art research facility.



The Company is a pre-clinical stage biopharmaceutical group developing new medicines and treatments to treat blood and autoimmune disease and to bring the curative power of bone marrow transplantation to a greater number of patients suffering from otherwise incurable life-threatening diseases. Hemogenyx Pharmaceuticals is developing several distinct and complementary product candidates, as well as a platform technology that it uses as an engine for novel product development.



For more than 50 years, bone marrow transplantation has been used to save the lives of patients suffering from blood diseases. The risks of toxicity and death that are associated with bone marrow transplantation, however, have meant that the procedure is restricted to use only as a last resort. The Company's technology has the potential to enable many more patients suffering from devastating blood diseases such as leukemia and lymphoma, as well as severe autoimmune diseases such as multiple sclerosis, aplastic anemia and systemic lupus erythematosus (Lupus), to benefit from bone marrow transplantation.


About H.C. Wainwright & Co.

H.C. Wainwright is a full‐service investment bank dedicated to providing corporate finance, strategic advisory and related services to public and private companies across multiple sectors and regions. H.C. Wainwright & Co. also provides research and sales and trading services to institutional investors. According to Sagient Research Systems, H.C. Wainwright's team is ranked as the #1 Placement Agent in terms of aggregate CMPO (confidentially marketed public offering), RD (registered direct offering) and PIPE (private investment in public equity) executed cumulatively since 1998.

checkricky
10/1/2022
08:27
Oh dear Pikey....Can you ask MadVlad how much is left in the bank?....and tell him to answer honestly, if he capable...
badger60
10/1/2022
08:26
hxxps://my.ct.events/register.aspx?meid=22d2962c-a482-43a2-8aad-53f12bd1b3da&;rpid=41d6be82-5fdd-4e3a-b857-a774c4e1a118
checkricky
10/1/2022
08:24
To stay up to date you can register with the link below for the H.C. Wainwright BIOCONNECT Virtual Conference Starts this Monday 10th January till the 13th January 2022

hxxps://my.ct.events/register.aspx?meid=22d2962c-a482-43a2-8aad-53f12bd1b3da&;rpid=41d6be82-5fdd-4e3a-b857-a774c4e1a118

As per last RNS:
Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, is pleased to announce its participation in the H.C. Wainwright Bioconnect Conference, in which the Company will be featured as a presenting company. The conference will be held on a virtual platform from January 10-13, 2022.


As part of the Company's presentation, Dr. Vladislav Sandler, CEO of Hemogenyx Pharmaceuticals, will provide an overview of the Company's business and product candidates to conference attendees.

If you are an institutional investor and would like to listen to the Company's presentation, please click on the following link to register for the conference: hxxps://hcwevents.com/bioconnect/.

The conference will feature corporate presentations and panels both live and on-demand. Dr. Sandler's presentation is accessible using a webcast link.


Dr Vladislav Sandler, CEO & Co-Founder of Hemogenyx Pharmaceuticals, commented: "Our presentation at the H.C. Wainwright Bioconnect Investment Conference provides the Company with a great opportunity to inform the investment community about our achievements and increase the Company's visibility globally. It also allows us to further establish Hemogenyx Pharmaceuticals as a leader in the development of medicines for the treatment of blood and autoimmune diseases."

About Hemogenyx Pharmaceuticals plc

Hemogenyx Pharmaceuticals is a publicly traded company (LSE: HEMO) headquartered in London, with its US operating subsidiaries, Hemogenyx Pharmaceuticals LLC and Immugenyx LLC, located in New York City at its state-of-the-art research facility.



The Company is a pre-clinical stage biopharmaceutical group developing new medicines and treatments to treat blood and autoimmune disease and to bring the curative power of bone marrow transplantation to a greater number of patients suffering from otherwise incurable life-threatening diseases. Hemogenyx Pharmaceuticals is developing several distinct and complementary product candidates, as well as a platform technology that it uses as an engine for novel product development.



For more than 50 years, bone marrow transplantation has been used to save the lives of patients suffering from blood diseases. The risks of toxicity and death that are associated with bone marrow transplantation, however, have meant that the procedure is restricted to use only as a last resort. The Company's technology has the potential to enable many more patients suffering from devastating blood diseases such as leukemia and lymphoma, as well as severe autoimmune diseases such as multiple sclerosis, aplastic anemia and systemic lupus erythematosus (Lupus), to benefit from bone marrow transplantation.


About H.C. Wainwright & Co.

H.C. Wainwright is a full‐service investment bank dedicated to providing corporate finance, strategic advisory and related services to public and private companies across multiple sectors and regions. H.C. Wainwright & Co. also provides research and sales and trading services to institutional investors. According to Sagient Research Systems, H.C. Wainwright's team is ranked as the #1 Placement Agent in terms of aggregate CMPO (confidentially marketed public offering), RD (registered direct offering) and PIPE (private investment in public equity) executed cumulatively since 1998.

checkricky
10/1/2022
08:19
Oh dear Pikey.....not much trading at 2p or over.
badger60
10/1/2022
06:05
Oi Pikey......

Plenty of CAR-T competition, and MadVlad still trying to find the starting blocks on his 3 legged mouse. I would guess that most of the other 158 companies are well post IND, and at various stages of phase level development ................and have much more than 5 Mio quid to play with.


Since the first historic CAR-T approvals in 2017, Kymriah (tisagenlecleucel), Yescarta (axicabtagene ciloleucel), Tecartus (brexucabtagene autoleucel), Breyanzi (lisocabtagene maraleucel), Abecma (idecabtagene vicleucel), and Relma-cel (relmacabtagene autoleucel) have reached commercialization.

Not to mention those that have already reached commercialisation (listed above).

badger60
10/1/2022
06:03
Oi Pikey....did you know that your stock fluffer employer, SPAngel is named after kiddies sweets that were given to under 5 year olds by nonces to groom them....... "Spangles"
Careful who you work for Pikey, it's probably already rubbed off on you......

badger60
09/1/2022
19:31
To stay up to date you can register with the link below for the H.C. Wainwright BIOCONNECT Virtual Conference Starts this Monday 10th January till the 13th January 2022

hxxps://my.ct.events/register.aspx?meid=22d2962c-a482-43a2-8aad-53f12bd1b3da&;rpid=41d6be82-5fdd-4e3a-b857-a774c4e1a118

As per last RNS:
Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, is pleased to announce its participation in the H.C. Wainwright Bioconnect Conference, in which the Company will be featured as a presenting company. The conference will be held on a virtual platform from January 10-13, 2022.


As part of the Company's presentation, Dr. Vladislav Sandler, CEO of Hemogenyx Pharmaceuticals, will provide an overview of the Company's business and product candidates to conference attendees.

If you are an institutional investor and would like to listen to the Company's presentation, please click on the following link to register for the conference: hxxps://hcwevents.com/bioconnect/.

The conference will feature corporate presentations and panels both live and on-demand. Dr. Sandler's presentation is accessible using a webcast link.


Dr Vladislav Sandler, CEO & Co-Founder of Hemogenyx Pharmaceuticals, commented: "Our presentation at the H.C. Wainwright Bioconnect Investment Conference provides the Company with a great opportunity to inform the investment community about our achievements and increase the Company's visibility globally. It also allows us to further establish Hemogenyx Pharmaceuticals as a leader in the development of medicines for the treatment of blood and autoimmune diseases."

About Hemogenyx Pharmaceuticals plc

Hemogenyx Pharmaceuticals is a publicly traded company (LSE: HEMO) headquartered in London, with its US operating subsidiaries, Hemogenyx Pharmaceuticals LLC and Immugenyx LLC, located in New York City at its state-of-the-art research facility.



The Company is a pre-clinical stage biopharmaceutical group developing new medicines and treatments to treat blood and autoimmune disease and to bring the curative power of bone marrow transplantation to a greater number of patients suffering from otherwise incurable life-threatening diseases. Hemogenyx Pharmaceuticals is developing several distinct and complementary product candidates, as well as a platform technology that it uses as an engine for novel product development.



For more than 50 years, bone marrow transplantation has been used to save the lives of patients suffering from blood diseases. The risks of toxicity and death that are associated with bone marrow transplantation, however, have meant that the procedure is restricted to use only as a last resort. The Company's technology has the potential to enable many more patients suffering from devastating blood diseases such as leukemia and lymphoma, as well as severe autoimmune diseases such as multiple sclerosis, aplastic anemia and systemic lupus erythematosus (Lupus), to benefit from bone marrow transplantation.


About H.C. Wainwright & Co.

H.C. Wainwright is a full‐service investment bank dedicated to providing corporate finance, strategic advisory and related services to public and private companies across multiple sectors and regions. H.C. Wainwright & Co. also provides research and sales and trading services to institutional investors. According to Sagient Research Systems, H.C. Wainwright's team is ranked as the #1 Placement Agent in terms of aggregate CMPO (confidentially marketed public offering), RD (registered direct offering) and PIPE (private investment in public equity) executed cumulatively since 1998.

checkricky
09/1/2022
19:29
hxxps://my.ct.events/register.aspx?meid=22d2962c-a482-43a2-8aad-53f12bd1b3da&;rpid=41d6be82-5fdd-4e3a-b857-a774c4e1a118
checkricky
09/1/2022
19:28
worth a read investors.....

It's highlights the importance in CAR-T and effectiveness at targeting cancer cells. CAR-T will eventually be able to treat many types of cancer. I know it's early days but I hope HEMO become global players In treating patients which can only be a big positive...Researcher, Dr Claire Roddie, said the treatment was "absolutely transformative" and probably the biggest breakthrough in the past 20 years in malignant blood cancers. HEMO are onto a real big game changing treatment I just can not wait for things to get moving and HEMO will hopefully be global players in this field.. This share can't be sticking around 2p very long now. Next few months and coming weeks will be very interesting indeed... Hope your all having a great weekend

checkricky
09/1/2022
19:26
You can't blame the Mad Badger60 from Thailand his a psychopath suffering from chronic mental disorder that explains his abnormal unstable social behaviour.
checkricky
Chat Pages: Latest  453  452  451  450  449  448  447  446  445  444  443  442  Older

Your Recent History

Delayed Upgrade Clock